Predictors of Response to 24-Week Telaprevir-Based Triple Therapy for Treatment-Naïve Genotype 1b Chronic Hepatitis C Patients
Table 1
Profile and laboratory data at the start of telaprevir-based peginterferon plus ribavirin combination therapy in patients infected with hepatitis C virus genotype 1b.
Demographic data
Number of patients
150
Gender (male/female)
82/68
Age (years)
58 (18–75)
Body weight (kg)
61.55 (41.2–115.8)
Body mass index (kg/m2)
23.4 (17.3–37.8)
Absence or presence of cirrhosis*
121/29
(noncirrhosis/cirrhosis)
Histological fibrosis of liver (F0/1/2/3/4/ND)
3/36/28/13/11/59
Genetic variations
rs8099917 (TT/TG or GG)
115/35
Amino acid substitutions in the HCV genotype 1b
Core amino acid substitution 70
97/53
(wild-type/mutant-type)**
Number of amino acid substitutions in ISDR (0-1/2≤)
114/36
Laboratory data
HCV-RNA ()
6.7 (5.0–7.8)
White blood cells (/μL)
5200 (2000–8700)
Hemoglobin (g/dL)
14.2 (11.0–17.5)
Platelets (×104/μL)
17.1 (7.0–35.3)
Aspartate aminotransferase (IU/L)
45 (13–221)
Alanine aminotransferase (IU/L)
49 (13–305)
Gamma-glutamyl-transpeptidase (IU/L)
40 (12–427)
Albumin (g/dL)
4.1 (3.3–4.7)
Fasting low density lipoprotein-cholesterol (mg/dL)
97.5 (21–194)
Fasting plasma glucose (mg/dL)
101 (74–210)
Homeostasis model assessment-insulin resistance
2.15 (0.68–13.45)
Alpha-fetoprotein (ng/mL)
4.5 (1–235)
Treatment
Initial dose of PEG-IFN (μg/kg)
1.50 (0.94–1.94)
Initial dose of RBV (mg/kg)
11.5 (6.6–14.0)
Initial dose of TVR (1500/2250 mg)
59/91
Initial dose of TVR (mg/kg)
30.6 (16.7–51.1)
PEG-IFN: peginterferon; RBV: ribavirin; TVR: telaprevir; HCV: hepatitis C virus; ISDR: interferon-sensitivity determining region; ND: not detected.
*Determined by the liver biopsy METAVIR scores within 12 months of enrollment or by an aspartate aminotransferase to platelet ratio index (APRI) >1.5.
**“Wild-type” (arginine) or “mutant-type” (glutamine or histidine). Data expressed as number of patients or median (range).
